...
首页> 外文期刊>Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society >Alpha-Fetoprotein Level > 1000 ng/mL as an Exclusion Criterion for Liver Transplantation in Patients With Hepatocellular Carcinoma Meeting the Milan Criteria
【24h】

Alpha-Fetoprotein Level > 1000 ng/mL as an Exclusion Criterion for Liver Transplantation in Patients With Hepatocellular Carcinoma Meeting the Milan Criteria

机译:α-甲胎蛋白水平> 1000 ng / mL作为符合米兰标准的肝细胞癌患者肝移植的排除标准

获取原文
获取原文并翻译 | 示例

摘要

Serum alpha-fetoprotein (AFP) has been increasingly recognized as a marker for a poor prognosis after liver transplantation (LT) for hepatocellular carcinoma (HCC). Many published reports, however, have included a large proportion of patients with HCC beyond the Milan criteria, and the effects of incorporating AFP as an exclusion criterion for LT remain unclear. We studied 211 consecutive patients undergoing LT for HCC within the Milan criteria according to imaging under the Model for End-Stage Liver Disease organ allocation system between June 2002 and January 2009. The majority (93.4%) had locoregional therapy before LT. The median follow-up was 4.5 years (minimum52 years). The Kaplan-Meier 1- and 5-year patient survival rates were 94.3% and 83.4%, respectively. In a univariate analysis, significant predictors of HCC recurrence included vascular invasion [hazard ratio (HR)510, 95% confidence interval (CI)53.9-26, P<0.001], a pathological tumor stage beyond the University of California San Francisco criteria (HR54.1, 95% CI51.36-12.6, P50.01), an AFP level> 1000 ng/mL (HR54.5, 95% CI51.3-15.3, P50.02), and an AFP level>500 ng/mL (HR53.1, 95% CI51.04-9.4, P50.04). In a multivariate analysis, vascular invasion was the only significant predictor of tumor recurrence (HR55.6, 95% CI51.9-19, P50.02). An AFP level>1000 ng/mL was the strongest pretransplant variable predicting vascular invasion (odds ratio56.8, 95% CI51.6-19.1, P50.006). The 1- and 5-year rates of survival without recurrence were 90% and 52.7%, respectively, for patients with an AFP level>1000 ng/mL and 95% and 80.3%, respectively, for patients with an AFP level≤1000 ng/mL (P50.026). Applying an AFP level>1000 ng/mL as a cutoff would have resulted in the exclusion of 4.7% of the patients from LT and a 20% reduction in HCC recurrence. In conclusion, an AFP level>1000 ng/mL may be a surrogate for vascular invasion and may be used to predict posttransplant HCC recurrence. Incorporating an AFP level> 1000 ng/mL as an exclusion criterion for LT within the Milan criteria may further improve posttransplant outcomes.
机译:血清甲胎蛋白(AFP)已被越来越多地视为肝细胞癌(HCC)肝移植(LT)后预后不良的标志。但是,许多已发表的报告都包括了米兰标准以外的大部分HCC患者,将AFP作为LT排除标准的影响尚不清楚。根据2002年6月至2009年1月的终末期肝病模型分配系统下的影像学,我们研究了米兰标准下连续211例接受LT的HCC肝癌患者。大多数(93.4%)的患者在LT之前接受了局部区域治疗。中位随访时间为4.5年(最少52年)。 Kaplan-Meier的1年和5年患者生存率分别为94.3%和83.4%。在单因素分析中,肝癌复发的重要预测因素包括血管浸润[危险比(HR)510、95%置信区间(CI)53.9-26,P <0.001],这是加利福尼亚大学旧金山分校标准以外的病理性肿瘤分期( HR54.1、95%CI51.36-12.6,P50.01),AFP水平> 1000 ng / mL(HR54.5、95%CI51.3-15.3,P50.02)和AFP水平> 500 ng / mL(HR53.1,95%CI51.04-9.4,P50.04)。在多变量分析中,血管浸润是肿瘤复发的唯一重要预测因子(HR55.6,95%CI51.9-19,P50.02)。 AFP水平> 1000 ng / mL是预测血管浸润的最强的移植前变量(几率56.8,95%CI51.6-19.1,P50.006)。 AFP水平> 1000 ng / mL的患者的1年和5年无复发生存率分别为90%和52.7%,AFP水平≤1000ng的患者分别为95%和80.3% / mL(P50.026)。将AFP水平> 1000 ng / mL作为临界值将导致4.7%的患者被排除在LT外,HCC复发减少20%。总之,AFP水平> 1000 ng / mL可能是血管入侵的替代指标,可用于预测移植后HCC的复发。在米兰标准中纳入AFP水平> 1000 ng / mL作为LT的排除标准,可以进一步改善移植后结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号